Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors L. Fong, P.M. Forde, J. D. Powderly, J. W. Goldman, J. J. Nemunaitis, J. John Luke, M. D. Hellmann, S. Kummar, R. C. Doebele, D. Mahadevan, S. M. Gadgeel, B. G. M. Hughes, B. Markman, M. J. Riese, J. Brody, L. A. Emens, I. Caffery, R. A. Miller, G. Laport
Title Safety and clinical activity of adenosine A2a receptor (A2aR) antagonist, CPI-444, in anti-PD1/PDL1 treatment-refractory renal cell (RCC) and non-small cell lung cancer (NSCLC) patients.
Journal
Vol
Issue
Date
URL http://abstracts.asco.org/199/AbstView_199_186068.html
Abstract Text J Clin Oncol 35, 2017 (suppl; abstr 3004)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung non-small cell carcinoma not applicable CPI-444 Phase I Actionable In a Phase I trial, treatment with single agent CPI-444 was well-tolerated and resulted in a disease control rate of 36% (4/11) in patients with non-small cell lung cancer (J Clin Oncol 35, 2017 (suppl; abstr 3004)). detail...
Unknown unknown renal cell carcinoma not applicable CPI-444 Phase I Actionable In a Phase I trial, treatment with single agent CPI-444 was well-tolerated and resulted in a disease control rate of 75% (3/4) in patients with renal cell carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 3004)). detail...
Unknown unknown renal cell carcinoma not applicable Atezolizumab + CPI-444 Phase I Actionable In a Phase I trial, treatment with the combination of CPI-444 and Tecentriq (atezolizumab) was well-tolerated and resulted in a disease control rate of 100% (3/3) in patients with renal cell carcinoma (J Clin Oncol 35, 2017 (suppl; abstr 3004)). detail...
Unknown unknown lung non-small cell carcinoma not applicable Atezolizumab + CPI-444 Phase I Actionable In a Phase I trial, treatment with the combination of CPI-444 and Tecentriq (atezolizumab) was well-tolerated and resulted in a disease control rate of 71% (5/7) in patients with non-small cell lung cancer (J Clin Oncol 35, 2017 (suppl; abstr 3004)). detail...